Skip to content

enVista Aspire™ Toric IOL ETA (REF ETAU150+260)Recalls & reported problems

Bausch & Lomb Incorporated · enVista Aspire toric hydrophobic acrylic IOL (non-preloaded) +26.00D SE / +1.50D CYL · Class 3 · Implant

All models of enVista Aspire Toric IOL (513)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
1
Deaths reported
0
Injuries reported
1
Recalls naming it
1

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 10757770621528), received between Jun 11, 2025 and Jun 11, 2025 — classified as 1 injury.

The most frequently reported specific device problem is “Insufficient Device Problem Information” (1 report).

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 1 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Recalls naming this device

  1. Mar 27, 2025Class IOpen, Classified

    In response to an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with implantation of enVista Aspire and enVista Envy IOLs, and certain enVista monofocal lenses in the U.S.

    Z-1679-2025 · Root cause: Process control · Recall details · FDA record ↗

Most reported problems

Device problems

  • Insufficient Device Problem Information1

Patient problems

  • Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available1
  • Hypopyon1
  • Toxic Anterior Segment Syndrome (TASS)1
  • Visual Disturbances1
  • Visual Impairment1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • InjuryJun 11, 2025Insufficient Device Problem Information; Insufficient Device Problem Information

    IT WAS REPORTED THAT 1 DAY AFTER IMPLANTATION OF AN INTRAOCULAR LENS (IOL) INTO THE LEFT EYE (OS), THE PATIENT PRESENTED WITH MODERATE WOUND EDEMA, 4+ CELL, FIBRIN & HYPOPYON. BASED ON THE FINDINGS, THE SURGEON CONCLUDED THE CAUSE AS TOXIC ANTERIOR SEGMENT SYNDROME (TASS). AS A PRECAUTION, THE PATIENT WAS IMMEDIATELY REFERRED TO RETINA FOR A CULTURE TO BE PERFORMED AND INTRAVITREAL INJECTIONS OF VANCOMYCIN & CEFTAZIDIME TO BE ADMINISTERED. THE FOLLOWING DAY THE PATIENT HAD AN ADDITIONAL ROUND OF INTRAVITREAL INJECTIONS OF VANCOMYCIN & CEFTAZIDIME. THERE WAS NO GROWTH FROM THE CULTURE. THE INFLAMMATION/TASS HAS FULLY RESOLVED. IN THE SURGEON'S OPINION, THE MOST LIKELY CAUSE OF THE EVENT IS THE LENS. ACCORDING TO THE SURGEON, PATIENT OUTCOME IS GOOD. ACCORDING TO THE CONSUMER, HER DISTANCE VISION IS BLURRY.

    Patient problems: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available; Hypopyon; Toxic Anterior Segment Syndrome (TASS); Visual Disturbances; Visual Impairment

    MAUDE report 22187346 ↗

Other Intraocular Lens devices

All Intraocular Lens devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page